1. Clinical Relevance of F-18-FDG PET and F-18-DOPA PET in Recurrent Medullary Thyroid Carcinoma
- Author
-
Anneke C. Muller Kobold, Thera P. Links, John T. M. Plukker, Anouk N A van der Horst-Schrivers, Hans H. G. Verbeek, Robert M.W. Hofstra, K. P. Koopmans, Jan Willem B. de Groot, Adrienne H. Brouwers, Clinical Genetics, Damage and Repair in Cancer Development and Cancer Treatment (DARE), and Guided Treatment in Optimal Selected Cancer Patients (GUTS)
- Subjects
Male ,IMPACT ,SEGMENTATION ,Carcinoembryonic antigen ,PROGNOSTIC-FACTORS ,Recurrence ,medullary thyroid carcinoma ,F-18-FDG PET ,medicine.diagnostic_test ,biology ,Middle Aged ,calcitonin doubling time ,CANCER ,Dihydroxyphenylalanine ,WBMTB ,Positron emission tomography ,Disease Progression ,Female ,Adult ,ELEVATED CALCITONIN LEVELS ,ANTIGEN DOUBLING TIMES ,Thyroid carcinoma ,Young Adult ,POSITRON-EMISSION-TOMOGRAPHY ,Fluorodeoxyglucose F18 ,CEA doubling time ,Carcinoma ,medicine ,MANAGEMENT ,Humans ,Radiology, Nuclear Medicine and imaging ,Thyroid Neoplasms ,Survival analysis ,Aged ,Retrospective Studies ,business.industry ,Cancer ,medicine.disease ,BIOCHEMICAL-EVIDENCE ,Survival Analysis ,Carcinoembryonic Antigen ,Carcinoma, Neuroendocrine ,carbohydrates (lipids) ,Calcitonin ,Positron-Emission Tomography ,biology.protein ,business ,Nuclear medicine ,Progressive disease ,F-18-DOPA PET - Abstract
The transition from stable to progressive disease is unpredictable in patients with biochemical evidence of medullary thyroid carcinoma (MTC). Calcitonin and carcinoembryonic antigen (CEA) doubling times are currently the most reliable markers for progression, but for accurate determination, serial measurements, which need time, are required. We compared F-18-FDG PET and F-18-dihydroxyphenylanaline (F-18-DOPA) PET with biochemical parameters and survival to assess whether these imaging modalities could be of value in detecting progressive disease. Methods: We evaluated the outcome of F-18-FDG PET or F-18-DOPA PET with calcitonin and CEA doubling times in 47 MTC patients. A subgroup of patients was included in the whole metabolic burden (WBMTB) analysis, with determination of standardized uptake values and number of lesions. WBMTB of F-18-DOPA PET and F-18-FDG PET was compared with biochemical parameters. Furthermore, survival was compared with F-18-DOPA PET or F-18-FDG PET positivity. Results: Doubling times were available for 38 of 40 patients undergoing F-18-FDG PET. There was a significant correlation with F-18-FDG PET positivity. Doubling times were less than 24 mo in 77% (n = 10/13) of F-18-FDG PET-positive patients, whereas 88% (n = 22/25) of F-18-FDG PET-negative patients had doubling times greater than 24 mo (P
- Published
- 2012